PhuturdexDrug Pipeline Intelligence

Phuturdex › Drugs › SI-B003

Drugs in development · updated 30 October 2026

SI-B003: clinical trials and development status

Development codeNot approved in the USNo EMA authorisation

As of 30 October 2026 SI-B003 is in 11 active clinical trials (recruiting or ongoing, phases I–III) for 13 diseases. The most advanced phase is II.

11Active trials
IIMost advanced phase
13Diseases studied

Summary updated every week · data as of 30 October 2026. In Phuturdex you can follow SI-B003 and get an email at every change or safety alert.

Sign in free →

Diseases studied

For each disease: the drug’s most advanced phase and active trials, with the reference trial on ClinicalTrials.gov.

DiseaseMost advanced phaseActive trialsReference trial
Head and neck squamous cell carcinomaII3NCT06668961
Non-small-cell lung carcinomaII3NCT05956587
Colorectal neoplasmII2NCT06008054
Breast neoplasmII1NCT06042894
Esophageal neoplasmII1NCT06008054
Lung small cell carcinomaII1NCT05924841
Nasopharyngeal CarcinomaII1NCT05956587
Stomach neoplasmII1NCT06008054
Transitional cell carcinomaII1NCT05965856
Uterine cervix neoplasmII1NCT05990803
MelanomaI1NCT04606472
Renal cell carcinomaI1NCT04606472
Triple-negative breast neoplasmI1NCT04606472

Everything on SI-B003

In Phuturdex you get every trial with sponsors, countries and dates, development events, FDA and EMA approvals, patents and exclusivities, orphan designations and safety alerts, with PDF and Excel export. Free until 31 March 2027.

Open in Phuturdex →

Source: Phuturdex analysis of ClinicalTrials.gov (U.S. National Library of Medicine), FDA and EMA data, updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III. Diseases are those named by each trial (NLM MeSH terms). The estimated launch, when shown, is a Phuturdex calculation described on the Method page, not official data.

ItalianoFrançaisDeutsch